A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Eltrekibart in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Eltrekibart in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development. The study will last approximately 62 weeks and may include up to 31 visits.
Inclusion Criteria:
Exclusion Criteria:
Murfreesboro, Tennessee 37130, United States
Bochum, North Rhine-Westphalia 44791, Germany
Wroclaw, Lower Silesian Voivodeship 50-566, Poland
Warsaw, Masovian Voivodeship 02-507, Poland
Malbork, Pomeranian Voivodeship 82-200, Poland